These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30194084)

  • 1. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.
    Galanina N; Goodman AM; Cohen PR; Frampton GM; Kurzrock R
    Cancer Immunol Res; 2018 Oct; 6(10):1129-1135. PubMed ID: 30194084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.
    Spano JP; Veyri M; Gobert A; Guihot A; Perré P; Kerjouan M; Brosseau S; Cloarec N; Montaudié H; Helissey C; Flament T; Gounant V; Lavolé A; Poizot-Martin I; Katlama C
    AIDS; 2019 Sep; 33(11):F13-F19. PubMed ID: 31259762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 5. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
    Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
    BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
    Uldrick TS; Wyvill KM; Kumar P; O'Mahony D; Bernstein W; Aleman K; Polizzotto MN; Steinberg SM; Pittaluga S; Marshall V; Whitby D; Little RF; Yarchoan R
    J Clin Oncol; 2012 May; 30(13):1476-83. PubMed ID: 22430271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
    Ostios-Garcia L; Faig J; Leonardi GC; Adeni AE; Subegdjo SJ; Lydon CA; Rangachari D; Huberman MS; Sehgal K; Shea M; VanderLaan PA; Cheng MP; Marty FM; Hammond SP; Costa DB; Awad MM
    J Thorac Oncol; 2018 Jul; 13(7):1037-1042. PubMed ID: 29631035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation.
    Daly ML; Fogo A; McDonald C; Morris-Jones R
    Clin Exp Dermatol; 2014 Jan; 39(1):7-12. PubMed ID: 23691969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study.
    Saller J; Walko CM; Millis SZ; Henderson-Jackson E; Makanji R; Brohl AS
    J Natl Compr Canc Netw; 2018 Jul; 16(7):797-800. PubMed ID: 30006421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
    Rajdev L; Jackie Wang CC; Joshi H; Lensing S; Lee J; Ramos JC; Baiocchi R; Ratner L; Rubinstein PG; Ambinder R; Henry D; Streicher H; Little RF; Chiao E; Dittmer DP; Einstein MH; Cesarman E; Mitsuyasu R; Sparano JA;
    Cancer; 2024 Mar; 130(6):985-994. PubMed ID: 37962072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
    Wu Y; Lin L; Shen Y; Wu H
    Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
    [No Abstract]   [Full Text] [Related]  

  • 17. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
    Tiu C; Wong A; Herschtal A; Mileshkin L
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
    Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
    Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
    J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.